Fig. 8.
Simulated pharmacokinetic (a) and pharmacodynamic (b) profiles using the final PK/PD model with parameter estimates of the phase IIa dataset and the combined phase IIa and IIb dataset once-daily oral dosing of 0.5 mg tesofensine for 14 weeks
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.